

CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: A2PUCU Asset Class: Stock

Company

2024/08/07 22:00:00



Price

0.33 USD

Difference ▼ -6.23% (-0.02)



Contact Details

CENTOGENE NV Tel: +49-381-80113400
-- Fax: +381-80113401
Am Strande 7 Web: <http://www.centogene.com>
18055 Rostock E-mail: -

Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|--------------------------------|------------|------------------------|------------|------------------------|-------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 48,625,000 | | 63,855,000 | | 58,539,000 | |
| Common stock capital | | 3,841,000 | | 3,529,000 | | 3,079,000 |
| Fixed assets | 36,603,000 | | 35,197,000 | | 44,597,000 | |
| Equity capital of a company | | -27,927,000 | | 7,909,000 | | 31,276,000 |
| Cash and cash equivalents | 21,097,000 | | 38,368,000 | | 20,262,000 | |
| Accrued liabilities | | 435,000 | | 277,000 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 47,904,000 | | 26,323,000 | | 44,914,000 |
| Prepayments and accrued income | | - | | - | | - |
| Non-current liabilities | | 58,955,000 | | 57,683,000 | | 17,816,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 320,000 | | 616,000 | | 0 |
| Total assets | 85,229,000 | 85,229,000 | 99,053,000 | 99,053,000 | 103,137,000 | 103,137,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|----------|-----------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 493 | 517 | 808 |
| Equity ratio | -32.77% | 7.98% | 30.54% |
| Debt-equity ratio | -405.18% | 1,152.35% | 227.46% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|-------|
| Tax Expense Rate | -0.82% | -0.28% | 0.05% |

CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: A2PUCU Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Turnover | 52,473,000 | 49,892,000 | 224,485,000 |
| Net income | -38,414,000 | -40,675,000 | -55,494,000 |
| EBIT | -26,211,777 | -33,117,450 | -48,942,034 |
| Operating income before taxes | -37,777,000 | -40,563,000 | -55,406,000 |
| Cash Flow | -40,796,000 | -32,997,000 | -26,007,000 |
| Net interest income | -8,640,000 | -3,749,000 | -1,002,000 |
| Research and development expenses | 11,221,000 | 15,303,000 | 18,198,000 |
| Income taxes | 310,000 | 112,000 | -28,000 |
| Result from investments in subsidiaries, associates and other | -326,000 | 0 | 0 |
| Revenues per employee | 95,750 | 86,816 | 249,934 |

Board of Directors

| | |
|------------------|-------------------------------|
| Peer Schatz | Chairman of Supervisory Board |
| Eric Sou tre | Member of Supervisory Board |
| Hubert Birner | Member of Supervisory Board |
| Jonathan Sheldon | Member of Supervisory Board |
| Guido Prehn | Member of Supervisory Board |
| Mary Sheahan | Member of Supervisory Board |

Members of Management Board

| | |
|-------------------|-------------------------------|
| Kim Stratton | Chairman of Managing Board |
| Ian Rentsch | Member of Executive Committee |
| Miguel Coego Rios | Member of Executive Committee |
| Peter Bauer | Member of Executive Committee |